Related by context. All words. (Click for frequent words.) 73 locoregional recurrence 72 advanced adenomas 71 cytoreductive surgery 71 malignant lesions 71 liver metastasis 71 lymph node metastases 70 metachronous 70 precursor lesions 70 axillary lymph nodes 70 pulmonary metastases 70 axillary node dissection 70 radical nephrectomy 70 bilateral oophorectomy 69 hormone receptor negative 69 peritoneal carcinomatosis 69 invasive lobular 69 colorectal neoplasms 69 atypical hyperplasia 68 renal tumors 68 nodal metastasis 68 axillary node 68 Adjuvant chemotherapy 68 salpingo oophorectomy 68 EBRT 68 pancreatic lung 68 invasive ductal 68 preoperative chemotherapy 68 endometrial carcinoma 68 nonmetastatic 68 nodal metastases 68 breast carcinoma 68 adjuvant radiation 68 Radical prostatectomy 68 ductal breast cancer 68 distant metastases 68 urothelial carcinoma 68 invasive carcinomas 68 postoperative chemotherapy 68 pCR 68 adenomatous 67 thyroid nodules 67 PSADT 67 debulking surgery 67 lung metastasis 67 EUS FNA 67 lymph node metastasis 67 HER2 positive tumors 67 benign lesions 67 mucinous 67 recurrent ovarian 67 breast carcinomas 67 hepatic metastases 67 lobular carcinoma 67 nonmelanoma skin cancers 67 catheter angiography 67 axillary nodes 67 liver metastases 67 ALND 67 colorectal carcinoma 67 lobular cancer 67 precancerous cervical 67 NMIBC 67 metastatic lymph nodes 66 ductal carcinomas 66 adrenalectomy 66 endometrial hyperplasia 66 intestinal metaplasia 66 axillary lymph node 66 cervical lymph nodes 66 adenoma 66 sentinel node 66 hamartomas 66 metastatic gastric 66 endometrial cancers 66 SLNB 66 pancreatic adenocarcinoma 66 renal cell carcinomas 66 leiomyomas 66 axillary dissection 66 contralateral breast cancer 66 nonischemic 66 sentinel lymph node biopsy 66 lymphadenectomy 66 gadolinium enhanced 66 epithelial ovarian 66 prostate carcinoma 66 ipsilateral breast 66 operable breast cancer 66 GISTs 66 Colon polyps 66 normal karyotype 66 advanced adenoma 66 locoregional 65 grade cervical intraepithelial 65 pelvic lymphadenectomy 65 prostate cancer CaP 65 proximal colon 65 thoracoscopic lobectomy 65 adjuvant radiotherapy 65 nephron sparing surgery 65 ovarian lung 65 #.#ng/ml 65 chemoembolization 65 androgen ablation 65 radiochemotherapy 65 cervical lymph node 65 ErbB2 positive 65 malignant prostate 65 adenomatous polyps 65 HGPIN 65 unresectable tumors 65 clinically localized prostate 65 hamartoma 65 curative resection 65 metastatic lesions 65 fallopian tube carcinoma 65 underwent resection 65 adnexal mass 65 radiotherapy RT 65 pulmonary metastasis 65 conventional angiography 65 pT3 65 colorectal adenoma 65 micrometastases 65 Thal Dex 65 BRCA1 mutation carriers 65 neoplasias 65 K ras mutations 65 situ LCIS 65 endoscopic resection 65 PCa 65 HER2 positive cancers 65 epithelial tumors 65 ovarian carcinoma 65 carcinoid tumor 65 malignant growths 65 biochemical recurrence 65 peritoneal cancer 65 invasive carcinoma 65 FDG uptake 65 oral clodronate 65 lymph node removal 65 benign nodules 65 lung metastases 65 breast cancer subtypes 65 lymphovascular invasion 65 extracapsular extension 65 colorectal polyp 64 underwent surgical resection 64 Papillary 64 metastatic pancreatic 64 esophagogastric junction 64 intima media thickness 64 resections 64 mediastinal 64 node metastases 64 prophylactic mastectomy 64 nephrectomy 64 CIN2 64 transurethral resection 64 tumor recurrence 64 histologic subtype 64 postoperative mortality 64 basal cell carcinoma BCC 64 invasive lobular carcinoma 64 breast lesions 64 graft occlusion 64 Endometrial 64 Hurthle cell 64 lymph node involvement 64 neoadjuvant chemotherapy 64 cervical lesions 64 distant metastasis 64 parathyroid 64 thyroglobulin 64 Barrett mucosa 64 gastrectomy 64 BRCA mutation carriers 64 Computerized tomography 64 sentinel nodes 64 cystectomy 64 chemoradiation therapy 64 colonic polyps 64 surgical debulking 64 HER2 negative 64 Contralateral 64 metastatic bladder 64 relapsed MM 64 CIN2 + 64 progesterone receptor negative 64 intestinal polyps 64 resected 64 colorectum 64 premalignant lesions 64 recurrent metastatic 64 androgen deprivation 64 contralateral 64 intact parathyroid hormone 64 resectable 64 benign ovarian 64 excisional biopsy 64 fibroma 64 undergoing radical prostatectomy 64 duodenal 64 chemoradiotherapy 64 radical prostatectomy RP 64 sarcomatoid 64 liver resection 64 Surgical resection 64 malignant ovarian 64 neoplastic 64 cytoreduction 64 KRAS mutations occur 64 BRCA deficient 64 carotid stenosis 64 brain metastases 64 osteosarcomas 64 thyroid nodule 64 retroperitoneal 64 ventricular dysfunction 64 KRAS mutations 63 biliary tract cancer 63 metastases 63 axillary lymph node dissection 63 mutated K ras 63 transfusion syndrome 63 basal cell cancers 63 histopathologic examination 63 leiomyoma 63 AGTR1 63 HER2 expression 63 LHRH receptor positive 63 pT2 63 gastroduodenal 63 recurrent VTE 63 malignant neoplasm 63 hepatocellular carcinomas 63 T2 lesions 63 mammographically 63 recurrent glioblastoma multiforme 63 neoplastic lesions 63 poorer prognosis 63 gastric adenocarcinoma 63 FDG-PET/CT 63 immunohistochemical staining 63 invasive coronary angiography 63 lung nodule 63 TNF blocker therapy 63 GSTP1 63 F FDG PET 63 lymph node dissection 63 oophorectomy 63 undergone radical prostatectomy 63 hyperplastic 63 osteoid osteoma 63 artery stenosis 63 LV dysfunction 63 cisplatin resistant 63 neoplastic cells 63 axilla 63 sentinel lymph nodes 63 total thyroidectomy 63 neoplasms 63 #Gy 63 CR nPR 63 micrometastasis 63 completely resected 63 carotid artery blockage 63 postoperative morbidity 63 submucosal 63 CYT# potent vascular disrupting 63 breast uterine 63 SUVmax 63 esophageal gastric 63 prostate adenocarcinoma 63 parathyroid carcinoma 63 tumor histology 63 postoperative complication 63 CT coronary angiography 63 thyroid carcinoma 63 PCA3 scores 63 polypoid 63 breast endometrial 63 LHRH agonists 63 BRAF mutation 63 stage IIIb IV 63 bladder prostate 63 pleomorphic 63 nondiabetic patients 63 perioperative complications 63 grade squamous intraepithelial 63 ipsilateral 63 ASCUS 63 FGFR2 gene 63 schwannomas 63 neoadjuvant treatment 63 neoplasia 63 biochemical relapse 63 resected pancreatic cancer 63 mL/min/#.# m 2 63 renal parenchyma 63 arteriography 63 gastroesophageal junction 63 histologically confirmed 63 pelvic lymph nodes 63 neoadjuvant therapy 63 neurofibromas 63 intraductal 63 pituitary adenomas 63 node dissection 63 computed tomographic 62 T1a 62 TRUS biopsy 62 lobular carcinomas 62 hematopoietic cancers 62 metastatic colorectal 62 CIN3 62 varicoceles 62 #F FDG PET 62 osteoid 62 Doxil ® 62 microsatellite instability 62 TRAIL R1 62 sentinel lymph node 62 papillary RCC 62 angiographically 62 plain radiographs 62 neoadjuvant 62 postoperative radiotherapy 62 HER2 overexpression 62 lymphocytosis 62 differentiated thyroid 62 hepatic lesions 62 squamous carcinoma 62 allogeneic HSCT 62 revascularization procedures 62 ductal cancer 62 estrogen receptor ER 62 Basal Cell 62 wedge resection 62 Basal cell 62 varices 62 mycophenolate mofetil 62 pneumonectomy 62 estrogen receptor progesterone receptor 62 ischemic lesions 62 sentinel node biopsy 62 extracranial 62 adjuvant therapies 62 hydronephrosis 62 gastric cardia 62 hypervascular 62 neoplasm 62 cystoscopic 62 BRAF V#E mutation 62 locoregional disease 62 underwent radical prostatectomy 62 prostate TURP 62 colon resection 62 IDH mutations 62 histologically 62 Ishak fibrosis score 62 ductal lobular 62 metaplasia 62 elevated CRP 62 distal colon 62 HER2 amplification 62 BRCA2 mutation carriers 62 hepatectomy 62 BRAF mutations 62 OPCAB 62 colon rectal 62 intravesical therapy 62 coronary artery stenosis 62 adenocarcinomas 62 colorectal gastric 62 mediastinoscopy 62 metastatic tumors 62 mammographic density 62 postoperative pathology 62 nonsmall cell lung cancer 62 sonographic findings 62 radioiodine therapy 62 carcinomas 62 pre malignant lesions 62 seminal vesicle invasion 62 standard chemotherapy regimens 62 adenoma recurrence 62 relapsed ovarian cancer 62 urethral stricture 62 nonalcoholic steatohepatitis NASH 62 fibrin deposition 62 ductal 62 paclitaxel eluting stents 62 supratentorial 62 hypoperfusion 62 paroxysmal AF 62 dysplastic lesions caused 62 carcinoma HCC 62 thromboembolisms 62 immunohistochemical 62 thymoma 62 Uterine cancer 62 histologically proven 62 pre cancerous polyps 62 adnexal masses 62 ERBB2 62 sleeve lobectomy 62 precancerous condition 62 serous ovarian cancer 62 histological subtype 62 external beam radiotherapy 62 FOLFOX6 62 skin sparing mastectomy 62 paragangliomas 62 tamoxifen Nolvadex ® 62 antiangiogenic therapy 62 lung nodules 62 posterior vitreous detachment 62 ALA PDT 62 androgen suppression 62 invasive ductal carcinoma 62 benign moles 62 Breast conserving 62 advanced neoplasia 62 prostatic tissue 62 varicocele 62 metastatic melanomas 62 osteolytic 61 papillomas 61 esophageal carcinoma 61 preoperative staging 61 gemcitabine Gemzar 61 ovarian endometrial 61 precancerous polyp 61 thymectomy 61 lymphomas leukemias 61 bowel cancers 61 HBeAg negative 61 hyperalgesia 61 TURP 61 stent stenosis 61 TACE 61 bone scintigraphy 61 detecting polyps 61 prognostic indicator 61 optical colonoscopy 61 median PFS 61 baseline LDH 61 Leydig cell 61 tumor excision 61 papillary renal cell carcinoma 61 endosonography 61 B7 H3 61 breast pancreatic 61 percutaneous biopsy 61 premalignant 61 chemotherapy cisplatin 61 medically inoperable 61 metastatic prostate 61 colorectal liver metastases 61 full thickness plication 61 cranial irradiation 61 fibrocystic 61 partial nephrectomy 61 enucleation 61 prostate radical prostatectomy 61 sonographically 61 response pCR 61 surgical excision 61 concurrent chemoradiation 61 taxane therapy 61 Folfox 61 grade glioma 61 tertile 61 Mitomycin C 61 precancers 61 lipomas 61 cervical intraepithelial neoplasia 61 gynecologic malignancy 61 renal pelvis 61 grade dysplasia 61 situ CIS 61 HER2 amplified 61 retransplantation 61 Endometrial cancer 61 cancer mCRC 61 orchidectomy 61 H. pylori eradication 61 recurrent NSCLC 61 lung lesions 61 benign polyps 61 intrahepatic 61 pancreatic prostate 61 TTF Therapy 61 lobular breast cancer 61 ADPKD 61 gastric cancers 61 arteriovenous fistula 61 intraperitoneal chemotherapy 61 FOLFOX4 61 p# mutation 61 intraoperative complications 61 5-FU/LV 61 hyperplastic polyps 61 stage IIIA 61 IDH1 mutation 61 abdominal hysterectomy 61 histological subtypes 61 BRCA mutations 61 papillary 61 repigmentation 61 nonfasting triglyceride levels 61 rebleeding 61 NSTE ACS 61 lumbar disk herniation 61 distal colon cancer 61 mesotheliomas 61 neoadjuvant radiation 61 malperfusion 61 oral antidiabetic medication 61 microcalcifications 61 estrogen receptor negative 61 stage IIIB 61 cerebral angiography 61 situs inversus 61 transrectal ultrasound guided 61 hormone therapy estrogen 61 GnRH agonists 61 prednisone prednisolone 61 HNSCC 61 Squamous 61 adriamycin 61 fallopian tube cancers 61 skeletal metastases 61 RALP 61 carboplatin paclitaxel 61 precancerous tissues 61 tumor resection 61 chromosomal mutations 61 malignant pleural mesothelioma 61 carcinoids 61 acute aortic dissection 61 SIADH 61 invasive ductal carcinomas 61 seminomas 61 hip BMD 61 adenomas 61 cystic lesions 61 bladder cancers 61 BRCA1 BRCA2 61 MGUS 61 gemcitabine carboplatin 61 Duodenal 61 nonmelanoma 61 endoscopic ultrasonography 61 chemoradiation 61 angiographic restenosis 61 endocrine therapies 61 perioperative mortality 61 pre cancerous lesion 61 mediastinal lymph nodes 61 T1c 61 Alessandro Riva 61 scintigraphic 61 pancreatic carcinoma 61 laparotomy 61 histopathologic findings 61 infiltrating ductal carcinoma 61 KRAS wild 61 TT genotype 61 pegylated liposomal doxorubicin 61 glycated hemoglobin levels 61 infarcts 61 morphometric vertebral fractures 61 bile duct cancers 61 hypercoagulable 61 Androgen deprivation therapy 61 laparoscopically assisted 61 breast conserving lumpectomy 61 mTOR inhibitors 61 androgen suppression therapy 61 HIV HCV coinfected 61 extracolonic findings 61 EGFR mutations 61 FDG PET 61 epididymal 61 thrombotic complications 61 complete cytogenetic response 61 contra lateral 61 Erythropoietic therapies may 61 ABVD 61 intra arterial chemotherapy 61 astrocytomas 61 squamous histology 61 CYPHER Stent 61 adjuvant therapy 61 meningiomas 61 BRCA1 mutations 61 eosinophil count 61 para aortic 61 transvaginal sonography 61 colorectal adenocarcinoma 61 choroidal neovascularization CNV 61 bladder ovarian 61 resistant hormone refractory 61 sonographically guided 61 Metastases 61 HER2 positive breast 61 atypical ductal hyperplasia 61 idraparinux 61 femoral neck fracture 61 symptomatic VTE 61 HER2 positivity 61 basal cell nevus syndrome 61 helical CT 61 oncologic outcomes 61 hippocampal atrophy 61 digital subtraction angiography 61 radiofrequency ablation RFA 61 PECAM 1 61 basal cell skin 61 papillary thyroid carcinoma 61 subclinical hyperthyroidism 60 X ray angiography 60 lobular 60 aneurysmal 60 perianal 60 pre cancerous growths 60 trabeculectomy 60 patients undergoing CABG 60 dysplastic nevi 60 cellularity 60 coronary calcification 60 ultrasonographic 60 vaginal hysterectomy 60 BRCA2 carriers 60 endometrioid 60 specific antigen PSA 60 Adenomas 60 extrapleural pneumonectomy 60 prostatic 60 hepatic resection 60 adjuvant hormonal therapy 60 transabdominal 60 endometrial 60 TNF α 60 HER2 positive metastatic breast 60 testicular germ cell 60 hepatoma 60 Computed tomographic 60 hypermethylated 60 chemo resistant 60 squamous cell carcinoma SCC 60 thromboembolic disease 60 radiation chemoradiation 60 perioperative morbidity 60 chlamydial infection 60 renal carcinoma 60 pre operatively 60 core needle biopsy 60 cytoreductive nephrectomy 60 benign prostatic hyperplasia enlarged 60 perfusion defects 60 INCB# [003] 60 transitional cell carcinoma 60 adenomatous polyp 60 cytological 60 metastatic lung cancer 60 antiangiogenic agents 60 CMV infections 60 xenograft models 60 prophylactic mastectomies 60 core needle biopsies 60 grade gliomas 60 mRNA expression 60 echogenicity 60 tortuosity 60 tibolone 60 pulmonary dysfunction 60 conformal radiotherapy 60 central retinal vein 60 MACCE 60 prognostic significance 60 minimally symptomatic 60 carotid IMT 60 IV bisphosphonates 60 fibroadenomas 60 T2 weighted images 60 castrate resistant 60 clinicopathological features 60 colorectal cancer liver metastases 60 adjunctive placebo 60 androgen dependent 60 PSA nadir 60 mutated KRAS 60 extracapsular 60 intracranial atherosclerosis 60 spiral computed tomography 60 systolic dysfunction 60 lymphangiogenesis 60 pathologic 60 thyrotropin levels 60 idarubicin 60 ischemic cardiomyopathy 60 pathologic correlation 60 unresectable stage 60 carotid artery thickness 60 myomas 60 anaplastic 60 undergoing coronary artery 60 paclitaxel cisplatin 60 Radiofrequency ablation 60 liver histology 60 axillary 60 bronchogenic carcinoma 60 prostate cancer CRPC 60 malignant nodules 60 aromatase inhibitor therapy 60 follicular thyroid cancer 60 dacarbazine DTIC 60 serum calcium levels 60 esophageal resection 60 deep venous thromboses 60 amyloid deposition 60 adjuvant tamoxifen 60 TroVax ® 60 esophagectomy 60 premalignant lesion 60 benign prostate 60 c MYC 60 upper endoscopy 60 mammary cancers 60 sonographic appearance 60 FDG PET imaging 60 myoma 60 epirubicin cyclophosphamide 60 prostate pancreatic 60 lung carcinomas 60 Kaplan Meier analysis 60 deCODE ProstateCancer TM 60 prostate cancer metastases 60 occlusive disease 60 stented vessel 60 TIMP 60 intravenous bisphosphonates 60 aminotransferase levels 60 cutaneous melanoma 60 peritoneal 60 cervical carcinoma 60 testicular tumors 60 colorectal tumors 60 lobectomy 60 tumoral 60 metastatic GIST 60 ascending aortic 60 penetrating keratoplasty 60 Sentinel node biopsy 60 situ DCIS 60 chronic prostatitis 60 nonproliferative 60 N. gonorrhoeae 60 genital lesions 60 adenomyosis 60 papillary carcinoma 60 malignant lymphoma 60 malignant phenotype 60 5FU 60 recurrent malignant glioma 60 KRAS mutation 60 urine cytology 60 pathologic diagnosis 60 intratumoral 60 multimodality therapy 60 spinal metastases 60 histologic examination 60 epithelioid 60 polycystic kidneys 60 atypia 60 polyp detection 60 SPINK1 60 stratifying patients 60 internal thoracic artery 60 nonfatal MI 60 ovarian cervical 60 radiosensitivity 60 malignant polyps 60 Breslow thickness 60 Vidaza ® 60 receptor tyrosine kinase inhibitor 60 uterine cervix 60 prostate cancer HRPC 60 sympathetic innervation 60 histologic subtypes 60 CYP#D# inhibitor 60 colonoscopic 60 benign noncancerous 60 Subgroup analysis 60 parenchymal 60 β blockers 60 calculi 60 obstructive coronary artery 60 atypical lobular hyperplasia 60 aortic coarctation 60 Hazard Ratio HR 60 armpit lymph nodes 60 advanced hepatocellular carcinoma 60 pseudoaneurysm 60 nonvertebral fractures 60 biliary tract 60 mediastinum 60 GSTT1 60 polyp recurrence 60 tumor subtype 60 orthotopic 60 pulmonary nodules 60 adjuvant chemotherapy 60 parenchyma 60 MALT lymphoma 60 leukemia multiple myeloma 60 node metastasis 60 trans retinoic acid 60 castration resistant 60 p# biomarker 60 tricuspid regurgitation 60 untreated metastatic melanoma 60 castration resistant hormone refractory 60 diagnostic modality 60 conventional coronary angiography 60 prognostic factor 60 #F FDG 60 % CI #.#-#.# [003] 60 invasive ductal breast cancer 60 reinfarction 60 colorectal tumor 60 anal lesions 60 osteochondroma 60 orchiectomy 60 carcinoid 60 underarm lymph nodes 60 underwent prostatectomy 60 computed tomographic scan 60 needle aspiration 60 biliary strictures 60 incisional 59 recanalization 59 refractory ischemia 59 corticosteroid therapy 59 AV fistulas 59 small lymphocytic lymphoma 59 precancerous tumors 59 supraclavicular 59 hypertrophic scars 59 appendiceal 59 basilar 59 glomerular 59 molecular subtypes 59 noninvasive outpatient 59 autologous transplantation 59 cytologic 59 oesophageal adenocarcinoma 59 preoperative PSA 59 densest breasts 59 splenic 59 pelvic radiotherapy 59 neointimal 59 atherosclerotic lesions 59 multidetector CT 59 benign breast 59 malignant tissue 59 temozolomide TMZ 59 MDCT angiography 59 myocardial reperfusion 59 chemotherapeutic regimens 59 pancreatic endocrine 59 relapsed SCLC 59 bone metastasis 59 removed laparoscopically 59 evaluating PRX# 59 Mitral valve 59 clinically detectable 59 renal allograft 59 metastatic RCC 59 FUSILEV enhances 59 colorectal neoplasia 59 histologic findings 59 KIT mutations 59 postoperative AF 59 calcified plaques 59 abdominal computed tomography 59 lymphadenopathy 59 recurrent DVT 59 neuroblastoma tumors 59 multivessel disease 59 hypervascular tumors 59 posttraumatic arthritis 59 Tumor shrinkage 59 multislice CT 59 localized renal 59 TMEM density 59 beta carotene supplementation 59 fine needle aspiration 59 platelet reactivity 59 gastric mucosa 59 gastric carcinoma 59 saphenous vein grafts 59 cancerous enlargement 59 computed tomography angiography 59 myocardial viability 59 thoracotomy 59 superficial bladder cancer 59 Fine needle aspiration 59 troponin T 59 rs# [002] 59 systolic function 59 systemic ALCL 59 GIST tumors 59 multivariate analyzes 59 T1 weighted images 59 atrophic gastritis 59 hilar 59 breast ovary 59 MGd 59 calcium antagonists 59 Lumpectomy 59 incomplete revascularization 59 metastatic bone 59 endometrial biopsy 59 uterine cancers 59 ovarian pancreatic 59 anticoagulants blood thinners 59 SLN biopsy 59 TAXUS Express Stent 59 hormonal treatments 59 anti angiogenic agents 59 pathologic examination 59 TNFa 59 CVD mortality 59 AVODART 59 XELOX 59 unresectable 59 transplantation HCT 59 antegrade 59 antitumor effect 59 EGFR mutation 59 dysplastic lesions 59 malignant pleural mesothelioma MPM 59 transarterial 59 intimal hyperplasia 59 prostate colon 59 cardiac computed tomography 59 thyrotoxicosis 59 glandular tissue 59 Lymph node 59 lateral radiograph 59 thromboembolism 59 tumor xenograft models 59 anterior uveitis 59 transurethral 59 dacarbazine 59 lenalidomide dexamethasone 59 neuroendocrine carcinoma 59 ureteric 59 hormone receptor positive 59 colectomy 59 malignant neoplasms 59 chemosensitivity 59 orchitis 59 hormone receptor status 59 immunohistochemical analysis 59 squamous 59 echocardiographic parameters 59 extramedullary 59 pretransplant 59 hormonal therapies 59 adrenal masses 59 oropharyngeal 59 chest radiographs 59 prostate abnormalities 59 antibody titer 59 carcinoembryonic antigen 59 univariate analysis 59 prognostic markers 59 IV NSCLC 59 underwent radical cystectomy 59 renal artery stenosis 59 serum creatinine levels 59 tirofiban 59 multivariate Cox 59 squamous cell lung cancer 59 hypointense 59 chemopreventive agent 59 titrated glipizide 59 ventricular myocardium 59 venography 59 paricalcitol 59 seminoma 59 cervix uteri 59 histologic